Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia

被引:42
作者
Barak, Segev [1 ]
Arad, Michal [1 ]
De Levie, Amaya [1 ]
Black, Mark D. [2 ]
Griebel, Guy [3 ]
Weiner, Ina [1 ]
机构
[1] Tel Aviv Univ, Dept Psychol, IL-69978 Tel Aviv, Israel
[2] Sanofi Aventis, CNS Dept, Bridgewater, NJ USA
[3] Sanofi Aventis, CNS Dept, Bagneux, France
基金
以色列科学基金会;
关键词
alpha 7 nicotinic receptors; cognition; latent inhibition; schizophrenia; positive symptoms; SSR180711; NITRIC-OXIDE SYNTHASE; ACETYLCHOLINE-RECEPTOR AGONISTS; NUCLEUS-ACCUMBENS DOPAMINE; ANIMAL-MODELS; PREPULSE INHIBITION; ALLOSTERIC MODULATOR; CONSTRUCT-VALIDITY; NEGATIVE SYMPTOMS; ACOUSTIC STARTLE; GATING DEFICITS;
D O I
10.1038/npp.2008.232
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Schizophrenia symptoms can be segregated into positive, negative and cognitive, which exhibit differential sensitivity to drug treatments. Accumulating evidence points to efficacy of alpha 7 nicotinic receptor (nAChR) agonists for cognitive deficits in schizophrenia but their activity against positive symptoms is thought to be minimal. The present study examined potential pro-cognitive and antipsychotic activity of the novel selective a7 nAChR partial agonist SSR180711 using the latent inhibition (LI) model. LI is the reduced efficacy of a previously non-reinforced stimulus to gain behavioral control when paired with reinforcement, compared with a novel stimulus. Here, no-drug controls displayed LI if non-reinforced pre-exposure to a tone was followed by weak but not strong conditioning (2 vs 5 tone-shock pairings). MK801 (0.05 mg/kg, i.p.)-treated rats as well as rats neonatally treated with nitric oxide synthase inhibitor L-NoArg (10 mg/kg, s.c.) on postnatal days 4-5, persisted in displaying LI with strong conditioning, whereas amphetamine (1 mg/kg) -treated rats failed to show LI with weak conditioning. SSR180711 (0.3, 1, 3 mg/kg, i.p.) was able to alleviate abnormally persistent LI produced by acute MK801 and neonatal L-NoArg; these models are believed to model cognitive aspects of schizophrenia and activity here was consistent with previous findings with alpha 7-nAChR agonists. In addition, unexpectedly, SSR180711 (1, 3 mg/kg, i.p.) potentiated LI with strong conditioning in no-drug controls and reversed amphetamine-induced LI disruption, two effects considered predictive of activity against positive symptoms of schizophrenia. These findings suggest that SSR180711 may be beneficial not only for the treatment of cognitive symptoms in schizophrenia, as reported multiple times previously, but also positive symptoms. Neuropsychopharmacology (2009) 34, 1753-1763; doi:10.1038/npp.2008.232; published online 21 January 2009
引用
收藏
页码:1753 / 1763
页数:11
相关论文
共 114 条
  • [1] Altered hippocampal circuit function in C3H α7 null mutant heterozygous mice
    Adams, C. E.
    Yonchek, J. C.
    Zheny, L.
    Collins, A. C.
    Steuens, K. E.
    [J]. BRAIN RESEARCH, 2008, 1194 : 138 - 145
  • [2] Schizophrenia, sensory gating, and nicotinic receptors
    Adler, LE
    Olincy, A
    Waldo, M
    Harris, JG
    Griffith, J
    Stevens, K
    Flach, K
    Nagamoto, H
    Bickford, P
    Leonard, S
    Freedman, R
    [J]. SCHIZOPHRENIA BULLETIN, 1998, 24 (02) : 189 - 202
  • [3] THE DISORDER OF CONSCIOUSNESS IN SCHIZOPHRENIA
    ANSCOMBE, R
    [J]. SCHIZOPHRENIA BULLETIN, 1987, 13 (02) : 241 - 260
  • [4] IMPROVED LEARNING AND MEMORY IN AGED RATS WITH CHRONIC ADMINISTRATION OF THE NICOTINIC RECEPTOR AGONIST GTS-21
    ARENDASH, GW
    SENGSTOCK, GJ
    SANBERG, PR
    KEM, WR
    [J]. BRAIN RESEARCH, 1995, 674 (02) : 252 - 259
  • [5] BARAK S, 2008, INT J NEURO IN PRESS
  • [6] The many faces of nitric oxide in schizophrenia. A review
    Bernstein, HG
    Bogerts, B
    Keilhoff, G
    [J]. SCHIZOPHRENIA RESEARCH, 2005, 78 (01) : 69 - 86
  • [7] SSR180711, a novel selective α7 nicotinic receptor partial agonist:: (I) binding and functional profile
    Biton, Bruno
    Bergis, Olivier E.
    Galli, Frederic
    Nedelec, Alain
    Lochead, Alistair W.
    Jegham, Samir
    Godet, Danielle
    Lanneau, Christophe
    Santamaria, Raphael
    Chesney, Francois
    Leonardon, Jacques
    Granger, Patrick
    Debono, Marc W.
    Bohme, Georg A.
    Sgard, Frederic
    Besnard, Francois
    Graham, David
    Coste, Annick
    Oblin, Andre
    Curet, Olivier
    Vige, Xavier
    Voltz, Corinne
    Rouquier, Liliane
    Souilhac, Josiane
    Santucci, Vincent
    Gueudet, Christiane
    Francon, Dominique
    Steinberg, Regis
    Griebel, Guy
    Oury-Donat, Florence
    George, Pascal
    Avenet, Patrick
    Scatton, Bernard
    [J]. NEUROPSYCHOPHARMACOLOGY, 2007, 32 (01) : 1 - 16
  • [8] On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia
    Black, MD
    Selk, DE
    Hitchcock, JM
    Wettstein, JG
    Sorensen, SM
    [J]. NEUROPHARMACOLOGY, 1999, 38 (09) : 1299 - 1306
  • [9] Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs
    Black, MD
    Simmonds, J
    Senyah, Y
    Wettstein, JG
    [J]. NEUROPHARMACOLOGY, 2002, 42 (03) : 414 - 420
  • [10] BLACK MD, 2008, PSYCHOPHARM IN PRESS